Notably, the inhibition of CCR2 using the small-molecule CCX872 improved the therapeutic benefits of anti-Programmed cell death protein 1 (PD-1)/Programmed cell death protein ligand 1 (PD-L1) immunotherapy in a syngeneic, orthotopic mouse model of pancreatic cancer [99]. Here, CCR2 is linked to familial pancreatic carcinoma.